A double-blind controlled evaluation of Actifed and its individual constituents in allergic rhinitis.
Pseudoephedrine and triprolidine, administered every 6 hours as a combination, made separate and distinct contributions to the treatment of allergic rhinitis. Furthermore, the combination was perceived by the patients as being clinically superior to either of its components or placebo.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D004809:Ephedrine / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D010919:Placebos; D054199:Pseudoephedrine; D011725:Pyridines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014311:Triprolidine / Q000627:therapeutic use*
D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D010919:Placebos; D011725:Pyridines; C006399:pseudoephedrine, triprolidine drug combination; D014311:Triprolidine; D054199:Pseudoephedrine; D004809:Ephedrine